GPC3 is an inclusion criterion in 9 clinical trials for hepatocellular carcinoma, of which 8 are open and 1 is closed. Of the trials that contain GPC3 status and hepatocellular carcinoma as inclusion criteria, 5 are phase 1 (4 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (1 open) [4].

GPC3 is an inclusion criterion in 4 clinical trials for malignant solid tumor, of which 3 are open and 1 is closed. Of the trials that contain GPC3 status and malignant solid tumor as inclusion criteria, 4 are phase 1 (3 open) [4].

GPC3 is an inclusion criterion in 2 clinical trials for hepatoblastoma, of which 1 is open and 1 is closed. Of the trials that contain GPC3 status and hepatoblastoma as inclusion criteria, 2 are phase 1 (1 open) [4].

GPC3 is an inclusion criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 0 are open and 1 is closed. Of the trial that contains GPC3 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (0 open) [4].

GPC3 is an inclusion criterion in 1 clinical trial for cancer, of which 1 is open and 0 are closed. Of the trial that contains GPC3 status and cancer as inclusion criteria, 1 is phase 1 (1 open) [4].

GPC3 is an inclusion criterion in 1 clinical trial for esophageal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains GPC3 status and esophageal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

GPC3 is an inclusion criterion in 1 clinical trial for gastric carcinoma, of which 0 are open and 1 is closed. Of the trial that contains GPC3 status and gastric carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].